Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, a substantial increase from $2 million in the year-ago period. The growth was driven by approximately $11 million in net sales of TONMYA, the company's recently approved treatment for fibromyalgia. TONMYA recorded 12,592 total prescriptions during the quarter, up 100% sequentially, with new patient prescriptions increasing 36% and refills rising 207%. This commercial momentum underscores the market's acceptance of the first new fibromyalgia therapy in over 15 years.
The company also highlighted that TONMYA currently has coverage representing approximately 136 million lives across commercial, managed Medicare, and Medicaid channels. Coverage is expected to expand to approximately 145 million lives when a managed Medicare agreement takes effect on Jan. 1, 2027. This broad reimbursement footprint is crucial for patient access and continued sales growth.
Beyond commercial achievements, Tonix is advancing its clinical pipeline. The company has enrolled the first patient in the potentially pivotal Phase 2 HORIZON study of TNX-102 SL for major depressive disorder (MDD). Additionally, Tonix is preparing to begin an adaptive Phase 2 field study of TNX-4800 for Lyme disease prevention in the first quarter of 2027, pending final FDA review and agreement on the protocol. These programs reflect Tonix's commitment to addressing high unmet medical needs in CNS and immunology.
Financially, Tonix ended the quarter with approximately $176.2 million in cash and cash equivalents. The company stated that its resources, together with third-quarter equity proceeds to date, are expected to fund planned operations and capital expenditures into early second-quarter 2027. This cash runway provides a solid foundation for executing its commercial and clinical strategies.
The strong quarterly performance is a testament to Tonix's ability to commercialize TONMYA effectively. The significant increase in prescriptions and revenue signals robust demand and successful market penetration. As coverage expands and the clinical pipeline progresses, Tonix is positioning itself for sustained growth in the CNS and immunology sectors.
For more information, visit the company's newsroom at https://nnw.fm/TNXP.
